DENTSPLY SIRONA (XRAY) has drawn fresh attention after expanding its relationship with Midwest Dental, giving Midwest access to the company’s technology portfolio across the United States starting November 1, 2026.
For context, DENTSPLY SIRONA’s share price has come under pressure, with the stock down 15.5% on a 30 day basis and 39% over 90 days, while the 1 year total shareholder return has declined 30.5%. This points to fading momentum despite recent commercial announcements.
Scan how DENTSPLY SIRONA compares with other pressured healthcare equipment players by running through our hand picked list of solid balance sheet and fundamentals (25 results) for potential ideas with sturdier finances.
DENTSPLY SIRONA keeps signing more distribution deals while the share price keeps sliding. The business reach looks broader. The question now is whether the US$8.57 tag fairly reflects that or overcompensates for the pressure.
Most Popular Narrative: 36% Undervalued
DENTSPLY SIRONA’s most followed valuation narrative pegs fair value at $13.40, well above the recent $8.57 close. This puts a spotlight on how its product and cost programs could feed into that valuation gap.
Active cost reduction programs, operational streamlining, and supply chain optimization are in progress. Management has indicated a stronger urgency to go "deeper and faster," potentially boosting EBITDA margin and cash flow generation through both lower SG&A and more efficient manufacturing.
Management's focus on closer customer relationships, clinician workflow enhancements, and proceduralization is expected to drive sales force effectiveness and bolster share in aesthetic and restorative segments. These are areas benefiting from heightened health awareness and the global trend toward elective and preventive dental procedures.
See why 10 investors see DENTSPLY SIRONA as 36% undervalued.
Result: Fair Value of $13.40 (UNDERVALUED)
Still, the analyst story around DENTSPLY SIRONA can break if tariff costs bite harder than expected or if U.S. elective procedures remain weak for a longer period.
Find out about the key risks to this DENTSPLY SIRONA narrative.
Next Steps
If this mix of pressure and potential around DENTSPLY SIRONA feels conflicted, treat that as your cue to move fast and test the numbers yourself. To see what optimistic investors are focusing on, review the 3 key rewards.
Looking for more DENTSPLY SIRONA sized ideas?
If DENTSPLY SIRONA’s setup has you thinking harder about where to put fresh capital, widen your lens now and scan other opportunities before they slip by.
- Target stronger downside protection by reviewing 32 resilient stocks with low risk scores that prioritise resilience when conditions turn against you.
- Hunt for better value by checking the 20 high quality undiscovered gems that pair solid fundamentals with lighter market attention.
- Boost income potential by assessing the 8 dividend fortresses that combine higher yields with steadier payout profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com